ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection
Chronic Hepatitis C
Compensated Cirrhosis and Non-cirrhotics
Human Immunodeficiency Virus Infection

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: ribavirin

First Posted Date: 2013-09-11

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 318

Registration Number: NCT01939197

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Phase 3

Completed

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: Fluvoxamine maleate
Drug: Placebo

First Posted Date: 2013-09-02

Last Posted Date: 2017-12-04

Lead Sponsor: AbbVie

Target Recruit Count: 38

Registration Number: NCT01933919

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis

Interventions: Other: placebo
Drug: Elagolix

First Posted Date: 2013-08-29

Last Posted Date: 2018-09-07

Lead Sponsor: AbbVie

Target Recruit Count: 815

Registration Number: NCT01931670

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection
Chronic Hepatitis C

Interventions: Drug: ABT-450/r/ABT-267
Drug: ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2013-07-30

Last Posted Date: 2018-05-30

Lead Sponsor: AbbVie

Target Recruit Count: 38

Registration Number: NCT01911845

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-354
Drug: Placebo

First Posted Date: 2013-07-25

Last Posted Date: 2013-12-11

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT01908010

Locations: 🇺🇸
Site Reference ID/Investigator# 106999, Miami, Florida, United States
🇺🇸
Site Reference ID/Investigator# 107000, Overland Park, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 106998, Orlando, Florida, United States

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Phase 2

Terminated

Conditions: Cardiothoracic Surgery
Vascular Surgery

Interventions: Drug: ABT-719
Drug: Placebo

First Posted Date: 2013-07-12

Last Posted Date: 2014-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 56

Registration Number: NCT01897519

Locations: 🇺🇸
Site Reference ID/Investigator# 103356, Boston, Massachusetts, United States
🇺🇸
Site Reference ID/Investigator# 102020, Cleveland, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 103355, Columbus, Ohio, United States

and more 20 locations

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Phase 2

Completed

Conditions: Cancer of the Blood and Bone Marrow
17p Deletion
Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-199 (Safety Expansion Cohort)
Drug: ABT-199 (Main Cohort)

First Posted Date: 2013-06-28

Last Posted Date: 2021-12-16

Lead Sponsor: AbbVie

Target Recruit Count: 158

Registration Number: NCT01889186

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey /ID# 92513, New Brunswick, New Jersey, United States
🇺🇸
Hackensack Univ Med Ctr /ID# 92500, Hackensack, New Jersey, United States
🇦🇺
Peter MacCallum Cancer Ctr /ID# 91795, Melbourne, Victoria, Australia

and more 45 locations

Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease

Completed

Conditions: Crohn's Disease

First Posted Date: 2013-05-23

Last Posted Date: 2017-06-16

Lead Sponsor: AbbVie

Target Recruit Count: 106

Registration Number: NCT01860846

Study Of Diabetic Nephropathy With Atrasentan

Phase 3

Terminated

Conditions: Diabetic Nephropathy

Interventions: Drug: Atrasentan
Drug: Placebo

First Posted Date: 2013-05-21

Last Posted Date: 2019-04-24

Lead Sponsor: AbbVie

Target Recruit Count: 5107

Registration Number: NCT01858532

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2013-05-21

Last Posted Date: 2020-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 1310

Registration Number: NCT01858519

Locations: 🇺🇸
Site Reference ID/Investigator# 116382, Anchorage, Alaska, United States
🇺🇸
Site Reference ID/Investigator# 116595, Long Beach, California, United States
🇺🇸
Site Reference ID/Investigator# 116441, Hartford, Connecticut, United States

and more 44 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy